3.0.0 828 2023-01-15T22:03:58Z 2023-01-15T22:03:58Z House H HR 2003-02-13 108 hsif00 Energy and Commerce Committee House Standing hsif14 Health Subcommittee Referred to 2003-02-26T20:54:44Z Referred to 2003-02-13T15:07:00Z 2003-02-26 hsif14 Health Subcommittee 1 House committee actions Referred to the Subcommittee on Health. Committee 2003-02-13 Referred to the House Committee on Energy and Commerce. IntroReferral H11100 2 House floor actions hsif00 Energy and Commerce Committee 2003-02-13 Introduced in House IntroReferral Intro-H 9 Library of Congress 2003-02-13 Introduced in House IntroReferral 1000 9 Library of Congress M000309 Rep. McCarthy, Carolyn [D-NY-4] CAROLYN MCCARTHY D NY 4 N E000287 Rep. Emanuel, Rahm [D-IL-5] Rahm Emanuel D IL 5 2003-02-13 True N000147 Del. Norton, Eleanor Holmes [D-DC-At Large] ELEANOR NORTON D DC HOLMES 0 2003-02-13 True O000159 Rep. Owens, Major R. [D-NY-11] MAJOR OWENS D NY R. 11 2003-02-13 True I000057 Rep. Israel, Steve [D-NY-2] STEVE ISRAEL D NY 2 2003-02-13 True R000011 Rep. Rahall, Nick J., II [D-WV-3] NICK RAHALL D WV J. 3 2003-02-25 False B001241 Rep. Bell, Chris [D-TX-25] Chris Bell D TX 25 2003-06-12 False P000149 Rep. Payne, Donald M. [D-NJ-10] DONALD PAYNE D NJ M. 10 2003-06-16 False R000053 Rep. Rangel, Charles B. [D-NY-15] CHARLES RANGEL D NY B. 15 2003-07-08 False Health Clinical trials Commerce Congress Congressional investigations Congressional reporting requirements Drug approvals Drug industry Drugs Economics and Public Finance Federal aid to research Generic drugs Government Operations and Politics Intellectual property Medical research Patents Pharmaceutical research Prescription pricing Profit Research and development Research grants Restrictive trade practices Science, Technology, Communications Small business Health 00 2003-02-13 Introduced in House 2006-11-28T17:35:40Z Amends the Public Health Service Act to require the Director of the National Institutes of Health to support qualifying clinical research on the development of new drugs at designated small public or private entities. Emphasizes drug research which has the potential to make a significant contribution for the prevention, diagnosis, or treatment of a disease which has not received significant Federal funding. Entitles the Director to five percent of the profits from sales during the patent period.

Requires the Comptroller General to study and report to Congress on the effects of: (1) Federal funding on the costs of research and the pricing of prescription drugs; and (2) pharmaceutical patent extensions and market exclusivity periods on delays in introducing generic versions.]]>

Pharmaceutical Fiscal Accountability Act of 2003 Display Title Pharmaceutical Fiscal Accountability Act of 2003 Official Title as Introduced To amend the Federal Food, Drug, and Cosmetic Act to allow certain applicants for approval of a generic drug to be eligible for a 180-day period of protection from competition, and for other purposes. Introduced in House IH Short Titles as Introduced Pharmaceutical Fiscal Accountability Act of 2003 Introduced in House 2003-02-13T05:00:00Z 2003-02-26 Referred to the Subcommittee on Health. text/xml EN Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain. Congressional Research Service, Library of Congress This file contains bill summaries and statuses for federal legislation. A bill summary describes the most significant provisions of a piece of legislation and details the effects the legislative text may have on current law and federal programs. Bill summaries are authored by the Congressional Research Service (CRS) of the Library of Congress. As stated in Public Law 91-510 (2 USC 166 (d)(6)), one of the duties of CRS is "to prepare summaries and digests of bills and resolutions of a public general nature introduced in the Senate or House of Representatives". For more information, refer to the User Guide that accompanies this file.